Article Figures & Data
Tables
- Table 1.
Evidence Table for Clinical Management Recommendations for Mammograms by Breast Imaging Reporting and Data System (BI-RADS) Category
BI-RADS Category Assessment Clinical Management Recommendation(s) Strength of Recommendation References Comments on References 0 Assessment incomplete Need to review prior studies and/or complete additional imaging A 3 All or none study; consensus guidelines 1 Negative Continue routine screening A 3, 8 Consensus guidelines; validated clinical decision tool 2 Benign finding Continue routine screening A 3, 8 Consensus guidelines; validated clinical decision tool 3 Probably benign finding Short-term follow-up mammogram at 6 months, then every 6 to 12 months for 1 to 2 years B 3, 6, 8, 10–15 Consensus guidelines; cohort studies; large case series; validated decision tool; less patient stress; lowered costs with surveillance 4 Suspicious abnormality Perform biopsy, preferably needle biopsy A 3, 8–10 All or none study; validated clinical decision tool 5 Highly suspicious of malignancy; appropriate action should be taken. Biopsy and treatment, as necessary. A 3, 8–10 All or none study; validated clinical decision tool 6 Known biopsy-proven malignancy, treatment pending Assure that treatment is completed - Table 2.
Mammography Assessment and Breast Cancers Detected in the New Hampshire Mammography Registry, 11/96 to 10/97, by Breast Imaging Reporting and Data System (BI-RADS) category
BI-RADS Category Baseline Mammography* Breast Cancers Detected Rate/1000 Anticipated Rate of Malignancy Following Biopsy Number Percentage 1 37,995 80.65% 0.7 —† 2 4,930 10.46% 1.2 —† 3 3,345 7.10% 8.1 <2%6–8 4 766 1.63% 135.8 23%–34%12–15 5 76 0.16% 605.3 ≥95%1,4,12–15 Total 47,112 100.00% * Data derived from Poplack et. al.5
† Categories 1 and 2 are considered to be negative test results.